Implantation of bulking agents for faecal incontinence. Update 2021: systematic review
Gassner L, Wild C
Record ID 32018001653
Authors' objectives: This systematic review aims to evaluate whether implantable bulking agents are superior or inferior to injectable bulking agents as second-line therapy in terms of clinical effectiveness and safety for faecal incontinence (FI).
Authors' results and conclusions: FI severity significantly improved sustainably, but not disease-related quality of life. Procedure-related adverse events hardly occurred. In nearly one quarter dislodgement of prostheses occurred. Studies were judged with moderate to high risk of bias and the strength of evidence for safety was judged to be very low.
Authors' recommendations: Implantable bulking agents might be a minimally invasive approach in FI treatment if conservative therapies fail.
Authors' methods: Six prospective uncontrolled trials were included.
Project Status: Completed
URL for project: https://www.hta.lbg.ac.at/page/bewertung-medizinischer-einzelleistungen-mel-2020/en
Year Published: 2021
URL for published report: https://eprints.aihta.at/1322/1/DSD_87_Update2021.pdf
URL for additional information: https://eprints.aihta.at/1322/
English language abstract: An English language summary is available
Publication Type: Full HTA
- Fecal Incontinence
- Prostheses and Implants
- Injections, Subcutaneous
- Biocompatible Materials
- Faecal incontinence
- bulking agents
- Systematic review
Organisation Name: Austrian Institute for Health Technology Assessment
Contact Address: Garnisongasse 7/20, A-1090 Vienna, Austria
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: HTA Austria - AIHTA GmbH
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.